MoonLake Immunotherapeutics (MLTX) Preferred Stock Liabilities (2020 - 2021)

MoonLake Immunotherapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $115.0 million for Q4 2021.

• On a quarterly basis, Preferred Stock Liabilities changed 0.0% year-over-year to $115.0 million in Q4 2021; TTM through Dec 2021 was $115.0 million, a 0.0% change from a year earlier, with the FY2021 full-year figure at $115.0 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities steadied at $115.0 million in Q4 2021 per MLTX's latest filing, from $115.0 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $115.0 million in Q4 2020 and bottomed at $107.3 million in Q2 2021.